Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: A prognostic study | Lippert J, et al | European Journal of Endocrinology | Aug. 2023

Lippert J, Dischinger U, Appenzeller S, Prete A, Kircher S, Skordilis K, et al. Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: A prognostic study. European Journal of Endocrinology. 2023;189(2):262-70.

Nonacus product: Germline

Abstract

Adrenocortical carcinoma (ACC) is a rare aggressive malignancy with heterogeneous clinical outcomes. Recent studies proposed a combination of clinical/histopathological parameters (S-GRAS score) or molecular biomarkers (BMs) to improve prognostication. We performed a comparative analysis of DNA-based BMs by evaluating their added prognostic value to the S-GRAS score.